We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





`Lab on a Chip` Test Could Detect COVID-19 Immune Response Faster Than Current Antibody Testing

By LabMedica International staff writers
Posted on 19 Jan 2021
A new antibody test being developed by researchers has the potential to detect the presence of antibodies generated in response to COVID-19 faster and with more accuracy than current antibody testing.

Conventional immunosensor antibody tests tend to be slow to show results and frequently inaccurate. More...
Researchers at the Southern Methodist University (Dallas, TX, USA) who are developing the new test estimate that the “Lab on a Chip” test could detect immune responses to coronavirus in two to three minutes, with just a drop of blood. The materials used to create the test are inexpensive, which should result in low-cost mass production. The chip is two cm in diameter, and the device is simple enough that those without medical training should be able to perform the test.

The test, which is called Multiplexed Assay for the Immune Response to COVID-19 (MAIRC), will look for signs that a person’s immune system has at some point responded to coronavirus being present in their body. Specifically, it will detect human IgG, IgM, and IgA antibodies that are produced when someone is or has been infected with the virus. The test is performed by applying a drop of blood to a microfluidic chip used to analyze tiny amounts of liquid. A filter embedded in the microchip extracts plasma from the blood sample. The chip is then placed into an electronic instrument that uses electric measurements to detect whether specific antibodies are present in the plasma. The same technology can potentially be used to detect other diseases that have known antibody-antigen binding.

The test can be performed anywhere via a smartphone. An additional detection method to measure how much of each type of antibody - IgG, IgM, or IgA - is found in a sample allows doctors to better track a person’s recovery to COVID-19. Because of the extra detection step, it will take two to three minutes for someone using “Lab on a Chip” for COVID detection to get results on their smartphone. In a trial, an earlier version of the device accurately detected IgG antibodies in 60 seconds using a small sample (just one ng/ml) of lab-bought antigens and antibodies. The precision and speed of “Lab on a Chip” are attributable, in part, to several innovations. One of those is the use of alternating current electrothermal (ACET) flows to bring antibodies in the blood plasma closer to sensor surfaces in the chip, so they can be detected.

The next step in the research will be testing the sensitivity and specificity of the device using lab-purchased human plasma samples spiked with lab-purchased antibodies and antibodies. The researchers will then test the device on plasma from actual COVID patients before it would be made available to the public. The researchers estimate the cost of the electronic instrument to read the chip would be about USD 15 to USD 20. The cost of the disposable cartridge, which is where a drop of blood would go, would likely be less than USD 1.

“There are some other techniques to detect antibodies quickly without using expensive laboratory equipment, but they suffer from sensitivity, accuracy, and consistency issues,” said J.-C. Chiao, one of the lead researchers behind the “Lab on a Chip” test. “Our ultimate goal is to create quantifiable, accurate, fast, and inexpensive diagnostic methods based on the detection of human IgG, IgM, and IgA antibodies. This does not currently exist, and it would have a deep and significant impact on the world, given the devastating effect this coronavirus pandemic has had.”

Related Links:
Southern Methodist University



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.